Leukocyte telomere length and its association with mammographic density and proliferative diagnosis among women undergoing diagnostic image-guided breast biopsy

Clara Bodelon; Christopher M. Heaphy; Alan K. Meeker; Berta Geller; Pamela M. Vacek; Donald L. Weaver; Rachael E. Chicoine; John A. Shepherd; Amir Pasha Mahmoudzadeh; Deesha A. Patel; Louise A. Brinton; Mark E. Sherman; Gretchen L. Gierach

doi:10.1186/s12885-015-1860-2

Table 3 Age-adjusted geometric mean of relative leukocyte telomere length (LTL) in relation to participant characteristics

From: Leukocyte telomere length and its association with mammographic density and proliferative diagnosis among women undergoing diagnostic image-guided breast biopsy

	All women (N = 195)		Proliferative diagnosis¹ (N = 141)		Non-proliferative diagnosis² (N = 54)		P-heterogeneity^¥
Characteristics	Mean LTL^§	(95 % CI) ^§	Mean LTL^§	(95 % CI) ^§	Mean LTL^§	(95 % CI) ^§
Age (years)							0.817
< 45	1.27	(1.05, 1.55)	1.47	(1.13, 1.91)	1.07	(0.80, 1.42)
45–49	1.35	(1.14, 1.60)	1.47	(1.20, 1.80)	1.10	(0.81, 1.50)
50–54	1.39	(1.17, 1.64)	1.46	(1.21, 1.77)	1.16	(0.82, 1.64)
≥ 55	1.23	(1.04, 1.45)	1.31	(1.09, 1.58)	0.94	(0.65, 1.37)
P-trend	0.774		0.423		0.745
Body mass index (Kg/m²)							0.194
< 25.0	1.24	(1.10, 1.39)	1.35	(1.18, 1.55)	0.93	(0.73, 1.17)
25.0–29.9	1.29	(1.09, 1.52)	1.44	(1.17, 1.78)	1.09	(0.83, 1.42)
≥ 30	1.56	(1.29, 1.90)	1.57	(1.26, 1.96)	1.56	(1.05, 2.31)
P-trend	0.058		0.248		0.030
Age at menarche (years)							0.743
≤ 12	1.26	(1.09, 1.45)	1.33	(1.13, 1.57)	1.01	(0.74, 1.37)
13	1.36	(1.17, 1.58)	1.53	(1.28, 1.83)	1.08	(0.83, 1.41)
≥ 14	1.33	(1.11, 1.58)	1.43	(1.17, 1.75)	1.08	(0.76, 1.53)
P-trend	0.613		0.530		0.787
Parity							0.739
Parous	1.30	(1.17, 1.43)	1.39	(1.24, 1.55)	1.07	(0.88, 1.30)
Nulliparous	1.35	(1.14, 1.61)	1.53	(1.23, 1.89)	1.08	(0.81, 1.44)
Age at first birth (years)^*							0.744
< 30	1.21	(1.08, 1.37)	1.30	(1.13, 1.50)	1.00	(0.79, 1.26)
≥ 30	1.51	(1.24, 1.83)	1.66	(1.31, 2.10)	1.28	(0.90, 1.81)
P-trend	0.066		0.084		0.246
Menopausal status							0.361
Premenopausal	1.37	(1.19, 1.57)	1.40	(1.18, 1.66)	1.22	(0.98, 1.51)
Postmenopausal	1.21	(0.98, 1.50)	1.45	(1.15, 1.82)	0.74	(0.47, 1.17)
Age at menopause (years)							0.221
< 45	1.37	(1.03, 1.84)	1.79	(1.30, 2.46)	0.67	(0.39, 1.17)
45–49	1.19	(0.94, 1.52)	1.28	(0.99, 1.66)	1.18	(0.68, 2.05)
≥ 50	1.24	(1.04, 1.48)	1.31	(1.09, 1.58)	0.80	(0.52, 1.22)
P-trend	0.655		0.166		0.654
Menopausal hormone therapy use^‡							0.461
Never	1.13	(0.95, 1.35)	1.26	(1.02, 1.57)	0.89	(0.60, 1.34)
Ever	1.49	(1.22, 1.80)	1.50	(1.23, 1.84)	1.10	(0.60, 2.01)
First degree family history of breast cancer							0.883
No	1.25	(1.13, 1.38)	1.35	(1.20, 1.51)	1.03	(0.85, 1.25)
Yes	1.50	(1.27, 1.78)	1.64	(1.34, 2.00)	1.19	(0.87, 1.61)

¹Diagnosis of hyperplasia, in-situ cancer or invasive cancer
²Diagnosis of benign or other discrete non-proliferative diagnosis
^§Based on linear regression with the log-transformed of the relative telomere length as outcome. Results are back-transformed. All characteristics were adjusted for age (continuous) and BMI (continuous), except age and BMI respectively
^¥P-value based on a Wald test in the regression model corresponding to an interaction term of the proliferative disease variable times the corresponding variable (coded in continuous form)
^*Restricted to parous women
^‡Restricted to post-menopausal women
The bolded numbers indicate statistical significance results at the 5 % level

Back to article page